Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Sponsor
Sichuan Cancer Hospital and Research Institute
Study ID
NCT04133337
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Lung Diseases
  • Neoplasms
  • Non-small-cell Lung Cancer
  • Respiratory Tract Diseases
  • Thoracic Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib Mesylate Tablets
  • SHR-1210 — DRUG
    Camrelizumab for Injection

Study Details

The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.

Key Dates

Start date
Nov 1, 2019
Status verified
Oct 2019
Primary completion
Jun 1, 2020
Completion
Jun 30, 2021

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Combined With SHR-1210 Injection
    * Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery. * Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion. * Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose.

Primary Outcome Measure

Major pathologic response rate(MPR)(<10% viable tumor cells) [ Time Frame: At time of surgery ]

Central Contacts

Related Studies